1. European Medicines Agency, ICH Topic Q6B Specifications: Test procedures and acceptance criteria for biotechnological/biological products, 1999.
2. U.S. Food and Drug Administration, Guidance for Industry: Q6B Specifications: Test procedures and acceptance criteria for biotechnological/biological products, 1999.
3. Cromwell MEM, Carpenter JF, Scherer T, Randolph TW. Opalescence in antibody formulations is a solution critical phenomenon. The 236th ACS National Meeting; August 17–21, 2008; Philadelphia, PA2008.
4. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93(6):1390–402.
5. Sukumar M, Doyle B, Combs J, Pekar A. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res. 2004;21(7):1087–93.